Table 2

Clinical findings at first-line evaluation in asymptomatic or mildly symptomatic SARS-CoV-2-positive junior athletes

Variablesn=571
Resting and exercise ECG
 Resting HR (bpm)78±15
 PR interval (ms)143±22.6
 First-degree atrioventricular block, n (%)4 (0.7)
 QRS interval (ms)84±9
 QRS axis (°)67±18
 Incomplete RBBB, n (%)90 (15.7)
 Complete RBBB, n (%)6 (1)
 QTc duration (ms)388±30
 Pathological T wave inversion, n (%)0 (0)
 Abnormal resting ECG, n (%)0 (0)
 Athletes with common PVBs during exercise testing, n (%)24 (4.2)
 Athletes with uncommon PVBs during exercise testing, n (%)0 (0)
 ST-T abnormalities during exercise, n (%)0 (0)
Echocardiography
 LV EDD (mm)45.9±5.0
 LV ESD (mm)27.6±4.5
 IVST (mm)7.8±1.2
 PWT (mm)7.7±1.2
 LV EF (%)63.5±4.7
 LV wall motion abnormalities, n (%)0 (0)
 Aortic root (mm)27.1±3.7
 Ascending aorta (mm)25.0±3.6
 Aortic arch (mm)21.3±2.9
 LA area (cm2)16.1±4.5
 LA volume (mL)29.5±9.8
 LA volume index (mL/m2)18.2±5.3
 Mid-cavity RV diameter (mm)28.2±7.2
 TAPSE (mm)24.2±3.1
 s’ velocity (m/s)0.14±0.02
 RV wall motion abnormalities, n (%)0 (0)
 IVC diameter (mm)16.6±4.5
Pericardial involvement, n (%)18 (3.2)
 Small pericardial effusion, n (%)15 (2.6)
 Moderate pericardial effusion, n (%)1 (0.2)
 Small pericardial effusion with a final diagnosis of pericarditis, n (%)2 (0.4)
Other abnormalities
 Bicuspid aortic valve6 (1.1)
 Mitral valve prolapse5 (0.9)
 Atrial septal defect1 (0.2)
 Patent foramen ovale4 (0.7)
 Patent ductus arteriosus1 (0.2)
  • IVC; inferior vena cava.EDD, end-diastolic diameter; EF, ejection fraction; ESD, end-systolic diameter; HR, heart rate; IVST, interventricular septum thickness; LA, left atrial; LV, left ventricular; PVB, premature ventricular beats; PWT, posterior wall thickness; RBBB, right bundle branch block; RV, right ventricular; TAPSE, tricuspid annular plane systolic excursion.